Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4457145
Max Phase: Preclinical
Molecular Formula: C24H16F3NO4S2
Molecular Weight: 503.52
Molecule Type: Unknown
Associated Items:
ID: ALA4457145
Max Phase: Preclinical
Molecular Formula: C24H16F3NO4S2
Molecular Weight: 503.52
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccc(S(=O)(=O)Nc2cccc(-c3ccc(C(=O)c4cc(F)c(F)c(O)c4F)s3)c2)cc1
Standard InChI: InChI=1S/C24H16F3NO4S2/c1-13-5-7-16(8-6-13)34(31,32)28-15-4-2-3-14(11-15)19-9-10-20(33-19)23(29)17-12-18(25)22(27)24(30)21(17)26/h2-12,28,30H,1H3
Standard InChI Key: XDBFOIZCTXHZMT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 503.52 | Molecular Weight (Monoisotopic): 503.0473 | AlogP: 5.88 | #Rotatable Bonds: 6 |
Polar Surface Area: 83.47 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 6.17 | CX Basic pKa: | CX LogP: 6.12 | CX LogD: 4.85 |
Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.25 | Np Likeness Score: -1.35 |
1. Abdelsamie AS, Herath S, Biskupek Y, Börger C, Siebenbürger L, Salah M, Scheuer C, Marchais-Oberwinkler S, Frotscher M, Pohlemann T, Menger MD, Hartmann RW, Laschke MW, van Koppen CJ.. (2019) Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing., 62 (3): [PMID:30645111] [10.1021/acs.jmedchem.8b01493] |
Source(1):